Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

89 A Novel, Modified-Release Drug Delivery Technology Containing Amphetamine-Ion Exchange Complexes.

Herman BK, King TR, Kando JC, Pardo A.

CNS Spectr. 2019 Feb;24(1):220. doi: 10.1017/S1092852919000671.

PMID:
30860002
2.

31 A Modified-Release Drug Delivery Technology Containing Amphetamine-Ion Exchange Complexes.

Herman BK, King TR, Kando JC, Pardo A.

CNS Spectr. 2019 Feb;24(1):191. doi: 10.1017/S1092852919000257.

PMID:
30859960
3.

88 The Efficacy and Safety of Amphetamine Extended-Release Oral Suspension (AMPH EROS) in Children with Attention-Deficit/Hyperactivity Disorder.

Kando JC, King T, Pardo A, Herman BK.

CNS Spectr. 2019 Feb;24(1):219-220. doi: 10.1017/S109285291900066X.

PMID:
30860001
4.

Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder.

Childress AC, Kando JC, King TR, Pardo A, Herman BK.

J Child Adolesc Psychopharmacol. 2019 Feb;29(1):2-8. doi: 10.1089/cap.2018.0078. Epub 2018 Dec 21.

5.

32 Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension (AMPH EROS) in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder.

Childress AC, Pardo A, King TR, Kando JC, Herman BK.

CNS Spectr. 2019 Feb;24(1):191-192. doi: 10.1017/S1092852919000269.

PMID:
30859961
6.

87 Efficacy Measures in an Open-label Dose-Optimization of an Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder.

Cutler A, Pardo A, King TR, Kando JC, Herman BK.

CNS Spectr. 2019 Feb;24(1):218-219. doi: 10.1017/S1092852919000658.

PMID:
30860000
7.

Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder.

Childress AC, Wigal SB, Brams MN, Turnbow JM, Pincus Y, Belden HW, Berry SA.

J Child Adolesc Psychopharmacol. 2018 Jun;28(5):306-313. doi: 10.1089/cap.2017.0095. Epub 2017 Dec 6.

8.

Sustained-release drug delivery system I: Coated ion-exchange resin system for phenylpropanolamine and other drugs.

Raghunathan Y, Amsel L, Hinsvark O, Bryant W.

J Pharm Sci. 1981 Apr;70(4):379-84.

PMID:
7229946
9.

Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.

Childress AC, Kollins SH, Cutler AJ, Marraffino A, Sikes CR.

J Child Adolesc Psychopharmacol. 2017 Feb;27(1):66-74. doi: 10.1089/cap.2016.0002. Epub 2016 May 16.

10.

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group.

Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

PMID:
14993578
11.

The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.

Childress AC, Brams M, Cutler AJ, Kollins SH, Northcutt J, Padilla A, Turnbow JM.

J Child Adolesc Psychopharmacol. 2015 Jun;25(5):402-14. doi: 10.1089/cap.2014.0176. Epub 2015 Feb 18.

12.

QuilliChew extended-release chewable tablets for the treatment of ADHD in patients ages 6 years old and above.

Childress A, Ponce De Leon B, Owens M.

Expert Opin Drug Deliv. 2018 Dec;15(12):1263-1270. doi: 10.1080/17425247.2018.1545759. Epub 2018 Nov 15.

PMID:
30404549
13.

A Randomized Phase I Study to Assess the Effect of Alcohol on the Pharmacokinetics of an Extended-release Orally Disintegrating Tablet Formulation of Amphetamine in Healthy Adults.

Newcorn JH, Stark JG, Adcock S, McMahen R, Sikes C.

Clin Ther. 2017 Aug;39(8):1695-1705. doi: 10.1016/j.clinthera.2017.07.006. Epub 2017 Jul 29.

PMID:
28760535
14.

New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.

Cortese S, D'Acunto G, Konofal E, Masi G, Vitiello B.

CNS Drugs. 2017 Feb;31(2):149-160. doi: 10.1007/s40263-017-0409-0. Review.

PMID:
28130762
15.

Pharmacokinetics of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Children with Attention-Deficit/Hyperactivity Disorder.

Stark JG, Engelking D, McMahen R, Sikes C.

J Child Adolesc Psychopharmacol. 2017 Apr;27(3):216-222. doi: 10.1089/cap.2016.0119. Epub 2016 Dec 12.

PMID:
27936898
17.

A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults.

Stark JG, Engelking D, McMahen R, Sikes C.

Postgrad Med. 2016 Sep;128(7):648-55. doi: 10.1080/00325481.2016.1216716. Epub 2016 Aug 11.

PMID:
27488574
18.

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.

May DE, Kratochvil CJ.

Drugs. 2010;70(1):15-40. doi: 10.2165/11530540-000000000-00000.

PMID:
20030423
19.

Development of sustained release fast-disintegrating tablets using various polymer-coated ion-exchange resin complexes.

Jeong SH, Park K.

Int J Pharm. 2008 Apr 2;353(1-2):195-204. doi: 10.1016/j.ijpharm.2007.11.033. Epub 2007 Nov 24.

PMID:
18164882
20.

Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.

Sikes C, Stark JG, McMahen R, Engelking D.

Clin Ther. 2017 Dec;39(12):2389-2398. doi: 10.1016/j.clinthera.2017.10.018. Epub 2017 Nov 23.

PMID:
29174216

Supplemental Content

Support Center